Skip to Main Content

Bibliografía

CAPÍTULO 1: INTRODUCCIÓN A LA COVID-19 Y A LAS ENFERMEDADES CARDIOVASCULARES

+
1. +
Zhou  P, Yang  X-L, Wang  X-G,  et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270–273.  [PubMed: 32015507]
+
2. +
Nishiga  M, Wang  DW, Han  Y, Lewis  DB, Wu  JC. COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives. Nat Rev Cardiol. 2020;17(9):543–558.  [PubMed: 32690910]
+
3. +
Lu  R, Zhao  X, Li  J,  et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet Lond Engl. 2020;395(10224):565–574.
+
4. +
Hoffmann  M, Kleine-Weber  H, Schroeder  S,  et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271–280.e8.  [PubMed: 32142651]
+
5. +
Sattar  Y, Ullah  W, Rauf  H,  et al. COVID-19 cardiovascular epidemiology, cellular pathogenesis, clinical manifestations and management. Int J Cardiol Heart Vasc. 2020;29:100589.  [PubMed: 32724831]

CAPÍTULO 2: COVID-19 Y SÍNDROME CORONARIO AGUDO (ACS)

+
1. +
Pinto  DS. Coronavirus disease 2019 (COVID-19): myocardial infarction and other coronary artery disease issues. UpToDate. 2020.
+
2. +
Cevik  M, Bamford  CGG, Ho  A. COVID-19 pandemic-a focused review for clinicians. Clin Microbiol Infect. 2020;26:842–847.  [PubMed: 32344166]
+
3. +
Liu  Y, Li  J, Feng  Y. Critical care response to a hospital outbreak of the 2019-nCoV infection in Shenzhen, China. Crit Care. 2020;24(1):56.  [PubMed: 32070391]
+
4. +
Libby  P, Loscalzo  J, Ridker  PM,  et al. Inflammation, immunity, and infection in atherothrombosis: JACC Review Topic of the Week. J Am Coll Cardiol. 2018;72:2071.  [PubMed: 30336831]
+
5. +
Mafham  MM, Spata  E, Goldacre  R,  et al. COVID-19 pandemic and admission rates for and management of acute coronary syndromes in England. Lancet. 2020;396(10248):381–389.  [PubMed: 32679111]
+
6. +
Wang  D, Hu  B, Hu  C,  et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. JAMA.[JAMA and JAMA Network Journals Full Text] 2020;323(11):1061–1069.  [PubMed: 32031570]

CAPÍTULO 3: COVID-19 Y TROMBOEMBOLIA

+
1. +
Wang  X, Sahu  KK, Cerny  J. Coagulopathy, endothelial dysfunction, thrombotic microangiopathy and complement activation: potential role of complement system inhibition in COVID-19. J Thromb Thrombolysis. 2021;51(3):657–662.  [PubMed: 33063256]
+
2. +
Gasecka  A, Borovac  JA, Guerreiro  RA,  et al. Thrombotic complications in patients with COVID-19: pathophysiological mechanisms, diagnosis, and treatment. Cardiovasc Drugs Ther. 2021;35(2):215–229.  [PubMed: 33074525]
+
3. +
Hadid  T, Kafri  Z, Al-Katib  A. Coagulation and anticoagulation in COVID-19. Blood Rev. 2020;Oct 8:100761.
+
4. +
Salem  N, Atallah  B, El Nekidy  WS, Sadik  ZG, Park  WM, Mallat  J. Thromboelastography findings in critically ill COVID-19 patients. J Thromb Thrombolysis. 2020;51(4):961–965.  [PubMed: 33011896]
+
5. +
Avila  J, Long  B, Holladay  D, Gottlieb  M. Thrombotic complications of COVID-19. ...

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.

Este sitio usa cookies. Al continuar navegando en este sitio, usted acepta nuestro uso de cookies. Más información Cerrar